Fig 1: Cell-SELEX, HTS, and aptamer binding analysis. (a) Schematic representation of the cell-SELEX procedure used. Eight rounds of conventional cell-SELEX in which the aptamer pool was first incubated with parental COS-7 (CD19-) non-target cell (counter-selection step) and then with COS-7/CD19+ target cells (positive selection step) were performed. In the last two rounds (IX and X), a cell-internalising SELEX procedure in which, downstream, the positive selection step, a treatment with proteinase K (PK), was introduced to deplete for aptamers bound on the cell surface. Internalised aptamers were then recovered by RNA extraction and RT-PCR. (b) Scattering plot representing the aptamers with at least 5 reads resulting by Illumina deep sequence analyses at rounds III and VIII. (c) Venn diagram showing the overlap in aptamers with at least 5 reads in the HTS analysis between conventional cell-SELEX (round VIII, blue circle) and cell-internalising SELEX (round X, yellow circle). (d) Frequency of the top four most abundant aptamers from HTS at round X. (e) B88, B85, and B97 aptamers (200 nM) were incubated with COS-7/CD19+ cells for 30 min at 37 °C. G0 starting aptamer pool was used as a control. Binding values (μM) were measured by qRT-PCR. Error bars show the mean of technical duplicates ± SEM values.
Fig 2: Aptamer miRNA delivery into CD19+ continuous and primary leukemic cells. (a,b) MEC-1 cells were treated with indicated molecules (400 nM) for 24 h. Then, cell culture medium was replaced with fresh medium without aptamers or conjugates and grown for an additional 24 h. MiR-16 (a) and miR-15a (b) levels were evaluated by qRT-PCR. U6 RNA was used as a reference gene. miRNA expression relative to cells treated with a control conjugate (SCRA-SCRAmiR) is reported in the graphs. Error bars show the mean ± SD values on technical replicates. (c,d) Jurkat cells were treated with indicated molecules (400 nM) for 24 h. Then, cell culture medium was replaced with fresh medium without aptamers or conjugates and grown for additional 24 h. miR-16 (c) and miR-15a (d) levels were evaluated by qRT-PCR. U6 RNA was used as a reference gene. miRNA expression relative to untreated cells is reported in the graphs. Error bars show the mean ± SD values on technical replicates. — (untreated cells); UN B85.T2-16 (unconjugated chimera B85.T2-miR-16); B85.T2-16 (chimera B85.T2-miR-16); B85.T2-SCRAmiR (control chimera with B85.T2 aptamer conjugated to a scrambled miR); SCRA-16 (control chimera with a control aptamer stick conjugated to miR-16); SCRA-SCRAmiR (control chimera with a control aptamer stick conjugated to a scrambled miR); UN B85.T2-15a (unconjugated chimera B85.T2-miR-15a); B85.T2-15a (chimera B85.T2-miR-15a); SCRA-15a (control chimera with a control aptamer stick conjugated to miR-15a). (e,f) CD19+ CLL patient-derived cells (CLL178) were treated with indicated molecules (400 nM) for 24 h. Then, cell culture medium was replaced with fresh medium without aptamers or conjugates and grown for an additional 24 h. miR-16 (e) and miR-15a (f) levels were evaluated by qRT-PCR. U6 RNA was used as a reference gene. miRNA expression relative to untreated cells is reported in the graphs. Error bars show the mean ± SD values on technical replicates. (g,h) CD19+ CLL patient-derived cells (CLL185) were treated with indicated molecules (400 nM) for 24 h. Then, cell culture medium was replaced with fresh medium without aptamers or conjugates and grown for an additional 24 h. miR-16 (g) and miR-15a (h) levels were evaluated by qRT-PCR. U6 RNA was used as a reference gene. miRNA expression relative to untreated cells is reported in the graphs. Error bars show the mean ± SD values on technical replicates. — (untreated cells); UN B85.T2-16 (unconjugated chimera B85.T2-miR-16); B85.T2-16 (chimera B85.T2-miR-16); B85.T2-SCRAmiR (control chimera with B85.T2 aptamer conjugated to a scrambled miR); SCRA-16 (control chimera with a control aptamer stick conjugated to miR-16); SCRA-SCRAmiR (control chimera with a control aptamer stick conjugated to a scrambled miR); SCRA6-16 (control chimera with a control aptamer stick conjugated to miR-16); SCRA6-15a (control chimera with a control aptamer stick conjugated to miR-15a); SCRA6-SCRAmiR (control chimera with a control aptamer stick conjugated to a scrambled miR); A9g-16 (control chimera with an unrelated A9g aptamer stick conjugated to miR-16); A9g-15a (control chimera with an unrelated A9g aptamer stick conjugated to miR-15a); A9g-SCRAmiR (control chimera with an unrelated A9g aptamer stick conjugated to a scrambled miR); B85.T2 + miR-16 (non-stick B85.T2 mixed with miR-16 stick); B85.T2 + miR-15a (non-stick B85.T2 mixed with miR-15a stick); miR-16 (miR-16 guide); miR-15a (miR-15a guide).
Fig 3: B88- and B85-derived short aptamers. (a,b) predicted secondary structures of B88 and B85 aptamers by RNA structure and design of two short versions for each aptamer (B88.T1, B88.T2, B85.T1, and B85.T2. (c,d) COS-7 and COS-7/CD19+ cells were treated with 200 nM of indicated aptamers for 30 min at 37 °C. Binding values (μM) were measured by qRT-PCR. Error bars show the mean of technical duplicates ± SEM values. (e,f) B88.T2 and B85.T2 serum stability. Aptamers (4 μM) were incubated in 80% human serum for indicated times. At each time point, RNA serum samples were collected and evaluated by electrophoresis on 15% denaturing polyacrylamide gel. Gels were stained with ethidium bromide and visualised at the Gel Doc EZ Imager. Gels representative of three independent experiments are shown (left panels). Original gels are available in Figure S8. Bands were quantified by using ImageJ program, and pixel intensity for each time point is reported in the graphs (right panels). Error bars show the mean of experimental triplicates ± SD values.
Fig 4: B85.T2 aptamer-binding activity. (a) Binding analysis of the B85.T2 aptamer on CD19+ MEC-1 cells and CD19− Jurkat leukaemia cells. Cells were pre-treated for 30 min at 37 °C with slow shaking with 0.4 µg/µL tRNA and 100 nM of biotinylated Ctrl Apt as unspecific competitors. Then, the B85.T2 FAM-labelled aptamer (250 nM) was added to cells for 30 min at 37 °C with slow shaking in the presence of competitors. Mean fluorescence was measured by FACS, cell auto-florescence was subtracted, and data were reported in the graph as fold increase of aptamer binding on MEC-1 over Jurkat. Error bars show the mean of experimental triplicates ± SD values. Statistics was calculated using Student’s t test, * p < 0.05 (b) Dose-dependent binding of the B85.T2 aptamer on MEC-1 cells. Cells were incubated with increasing concentrations of FAM-labelled aptamer for 30 min at 37 °C in serum-free medium. The mean fluorescence was measured at FACS, cell auto-florescence was subtracted, and data were reported in the graph. Error bars show the mean of experimental triplicates ± SEM values. (c) Aptamer-mediated pull-down. MEC-1 cells were incubated with 400 nM of the biotinylated B85.T2 aptamer or with a biotinylated control aptamer. Cell lysates were purified on magnetic streptavidin beads (Promega Corporation, Wisconsin, USA) and immunoblotted with an anti-CD19 antibody. A total of 4 μg of total cell extracts from MEC-1 cells (Input) were loaded as a reference. The original Western Blot is available in Figure S8. (d) Dose–response BLI binding interferograms of B85.T2 at concentrations between 2.5 and 100 nM to purified rhCD19 immobilised on ARG2 sensor-chips. Data are representative of triplicate experiments. (e) Dose–response binding curve of BLI signals at plateau (202 s) as a function of aptamer concentration. Data represent the average of triplicate experiments ± standard deviation (SD). (f) Dose–response BLI binding interferograms of the control aptamer (Ctrl Apt) at concentrations between 10 nM and 1 µM to purified rhCD19 immobilised on ARG2 sensor chips. Data are representative of triplicate experiments. (g) Dose–response BLI binding interferograms of B85.T2 at concentrations between 10 nM and 1 µM to purified rhBCMA immobilised on ARG2 sensor chips. Data are representative of triplicate experiments.
Supplier Page from OriGene Technologies for CD19 (NM_001178098) Human Untagged Clone